Roche upgraded to “buy” by HSBC with CHF320 target on obesity drug strategy
PositiveFinancial Markets

HSBC has upgraded Roche to a 'buy' rating, setting a target price of CHF320, largely due to the company's promising strategy in the obesity drug market. This upgrade is significant as it reflects confidence in Roche's ability to innovate and capture a growing segment of the pharmaceutical industry, which could lead to increased revenues and market share. Investors are likely to view this positively, as it suggests a strong future for Roche's product pipeline.
— Curated by the World Pulse Now AI Editorial System